Prognostic impact of MPV for non&#8211;squamous non&#8211;small cell lung cancer patients who received front line chemotherapy in combination with bevacizumab: A retrospective analysis.

Prognostic impact of MPV for non&#8211;squamous non&#8211;small cell lung cancer patients who received front line chemotherapy in combination with bevacizumab: A retrospective analysis. - MPV and Bevacitumab in NSCLC.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011018

Enrollment

250

Registered

2013-06-24

Start date

2013-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non&amp

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologicaly or cytologicaly diagnosed non-squamous NSCLC. Stage IV (7th edition) at initial diagnosis. Patients of non squamous NSCLC who received front line chemotherapy at Hirakata or Kansai Medical University Takii Hospital from November 2009 to April 2012.

Exclusion criteria

Exclusion criteria: Patients who lack adequate medical record. Patients who received thoracic irradiation with curative intention. Patients who were diagnosed as LC-NEC.

Design outcomes

Secondary

Measure	Time frame
Contribution of MPV for survival of NSCLC patients who received chemotherapy in combination with Bevacizumab.	—

Primary

Measure	Time frame
Biological effects of bevacizumab to MPV.	—

Countries

Japan

Contacts

Public ContactShosaku Nomura

Kansai Medical University 1st department of internal medicine

nomurash@hirakata.kmu.ac.jp072-804-0101

Outcome results